Tier 2 — strong

Quercetin does not affect rating of perceived exertion in athletes during the Western States endurance run

Alan C Utter, David C Nieman, Jie Kang, Charles L Dumke, John C Quindry, Steven R McAnulty, Lisa S McAnulty
Research in sports medicine (Print) 2009 17(2):71

Bibliography

PubMed
PMID 19479626
DOI
10.1080/15438620902901474
Funding
Funding was not specified in the indexed record or the disclosure metadata available for this entry.
Competing interests
A competing-interest declaration was not available in the indexed record or the disclosure metadata used for this entry.

Study snapshot

DesignRandomized double-blind placebo-controlled ultramarathon trial
ModelHuman intervention research
Sample63 randomized runners; 39 finishers
InterventionQuercetin 1,000 mg/day or placebo
Duration3 weeks before a 160-km race
EndpointsSource-specific outcomes described in the key findings

What the study showed, in plain terms

Published in 2009, this source examined exercise and recovery. Design: Randomized double-blind placebo-controlled ultramarathon trial. Sample/model: 63 randomized runners; 39 finishers. The exposure or intervention was Quercetin 1,000 mg/day or placebo. Follow-up or treatment period: 3 weeks before a 160-km race.

Perceived exertion and finishing times did not differ between groups.

Finisher analyses and a specialized endurance setting limit generalization. This reports another outcome from the same Western States trial.

Continue with Quercetin Data Center

For topic-level interpretation, read Quercetin for Exercise: Performance, Recovery and Muscle. This is a related guide; the citation panel separately identifies articles that directly cite this paper.

Key findings

  • Perceived exertion and finishing times did not differ between groups.
  • The recorded outcome domains were Source-specific outcomes described in the key findings.
  • The result applies to the tested exposure: Quercetin 1,000 mg/day or placebo; 3 weeks before a 160-km race.

What this study can and cannot tell us

  • Finisher analyses and a specialized endurance setting limit generalization. This reports another outcome from the same Western States trial.
  • An individual controlled trial must be interpreted alongside its comparator, sample size, endpoint selection and independent replication. It does not validate a different commercial formulation or a general longevity claim.
  • Companion or correction records are linked below. They should not be counted automatically as independent replications; see the individual source notes for the relationship.
  • Source basis: Source check: PubMed abstract and indexed metadata; full methods were not independently confirmed for this entry. Missing method details, funding information or participant denominators are not inferred.

Related papers in the corpus

Tier 2
Oral quercetin supplementation and blood oxidative capacity in response to ultramarathon competition
John C Quindry et al. · International journal of sport nutrition and exercise metabolism · 2008
Tier 2
Quercetin ingestion does not alter cytokine changes in athletes competing in the Western States Endurance Run
David C Nieman et al. · Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2007
Tier 2
Post-160-km race illness rates and decreases in granulocyte respiratory burst and salivary IgA output are not countered by quercetin ingestion
D Henson et al. · International journal of sports medicine · 2008
Tier 1
Quercetin supplementation promotes recovery after exercise-induced muscle damage: a systematic review and meta-analysis of randomized controlled trials
Daniel Rojano-Ortega et al. · Biology of sport · 2023
Tier 2
Effects of quercetin supplementation on endurance performance and maximal oxygen consumption: a meta-analysis
Denis M Pelletier et al. · International journal of sport nutrition and exercise metabolism · 2013

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology